7 results on '"Kukreti, Vishal"'
Search Results
2. Effectiveness and tolerability of first-line autologous stem cell transplant and maintenance rituximab for mantle cell lymphoma.
- Author
-
Falcone U, Jiang H, Bashir S, Tsang R, Kukreti V, Keating A, Crump M, and Kuruvilla J
- Subjects
- Adult, Aged, Female, Humans, Lymphoma, Mantle-Cell mortality, Maintenance Chemotherapy, Male, Middle Aged, Retrospective Studies, Survival Analysis, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation methods, Lymphoma, Mantle-Cell therapy, Rituximab therapeutic use
- Published
- 2018
- Full Text
- View/download PDF
3. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma.
- Author
-
Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Haliotis T, Albuquerque M, Fornika D, Alamouti S, Froment R, Greenwood CM, Oros KK, Camglioglu E, Sharma A, Christodoulopoulos R, Rousseau C, Johnson N, Crump M, Morin RD, and Mann KK
- Subjects
- Adult, Aged, DNA, Neoplasm blood, DNA, Neoplasm genetics, Female, Humans, Lymphoma, Large B-Cell, Diffuse blood, Lymphoma, Large B-Cell, Diffuse genetics, MEF2 Transcription Factors blood, MEF2 Transcription Factors genetics, Male, Middle Aged, Mutation, Neoplasm Proteins blood, Neoplasm Proteins genetics, Panobinostat, Recurrence, Hydroxamic Acids administration & dosage, Indoles administration & dosage, Lymphoma, Large B-Cell, Diffuse drug therapy, Rituximab administration & dosage
- Abstract
The majority of diffuse large B-cell lymphoma (DLBCL) tumors contain mutations in histone-modifying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (HDIs), and preclinical data suggest that HDIs augment the effect of rituximab. In this randomized phase 2 study, we evaluated the response rate and toxicity of panobinostat, a pan-HDI administered 30 mg orally 3 times weekly, with or without rituximab, in 40 patients with relapsed or refractory de novo (n = 27) or transformed (n = 13) DLBCL. Candidate genes and whole exomes were sequenced in relapse tumor biopsies to search for molecular correlates, and these data were used to quantify circulating tumor DNA (ctDNA) in serial plasma samples. Eleven of 40 patients (28%) responded to panobinostat (95% confidence interval [CI] 14.6-43.9) and rituximab did not increase responses. The median duration of response was 14.5 months (95% CI 9.4 to "not reached"). At time of data censoring, 6 of 11 patients had not progressed. Of the genes tested for mutations, only those in MEF2B were significantly associated with response. We detected ctDNA in at least 1 plasma sample from 96% of tested patients. A significant increase in ctDNA at day 15 relative to baseline was strongly associated with lack of response (sensitivity 71.4%, specificity 100%). We conclude that panobinostat induces very durable responses in some patients with relapsed DLBCL, and early responses can be predicted by mutations in MEF2B or a significant change in ctDNA level at 15 days after treatment initiation. This clinical trial was registered at www.ClinicalTrials.gov (#NCT01238692)., (© 2016 by The American Society of Hematology.)
- Published
- 2016
- Full Text
- View/download PDF
4. Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab.
- Author
-
Salmasi G, Li M, Sivabalasundaram V, Panzarella T, Tsang R, Kukreti V, Crump M, and Kuruvilla J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide therapeutic use, Doxorubicin therapeutic use, Female, Humans, Incidence, Lung Diseases, Interstitial chemically induced, Male, Middle Aged, Prednisone therapeutic use, Retrospective Studies, Rituximab adverse effects, Vincristine therapeutic use, Young Adult, Antineoplastic Agents therapeutic use, Lung Diseases, Interstitial epidemiology, Lymphoma, Non-Hodgkin drug therapy, Rituximab therapeutic use
- Abstract
Rituximab is a monoclonal anti-CD20 antibody that is standard of care for treatment of B-cell non-Hodgkin lymphoma (NHL). The purpose of this study was to quantify the incidence of rituximab (R)-related interstitial pneumonitis (IP) in patients with NHL receiving immunochemotherapy. All patients with NHL who received cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), cyclophosphamide, vincristine and prednisone (CVP), R-CHOP or R-CVP in Princess Margaret Hospital between June 1998 and August 2009 were retrospectively reviewed. We compared cohorts of patients who did and did not receive R and documented the incidence of IP during and/or post-treatment. In total 560 patients were included in this analysis. The rate of IP in the entire cohort was 2.9% (16/560) with a trend toward a higher rate in the R group (3.95% vs. 1.3% [odds ratio 3.1, 0.84-17.27, p = 0.074]). Baseline pulmonary computed tomography abnormalities in patients with lymphoma are relatively common. The addition of R to chemotherapy does not significantly increase the risk of symptomatic chemotherapy-related IP.
- Published
- 2015
- Full Text
- View/download PDF
5. Chemoimmunotherapy resistant follicular lymphoma: predictors of resistance, association with transformation and prognosis.
- Author
-
Mozessohn, Lee, Cheung, Matthew C., Crump, Michael, Buckstein, Rena, Berinstein, Neil, Imrie, Kevin, Kuruvilla, John, Piliotis, Eugenia, and Kukreti, Vishal
- Subjects
LYMPHOMA treatment ,HEALTH outcome assessment ,DRUG resistance ,PHARMACOLOGY ,CANCER chemotherapy ,RITUXIMAB ,PROGNOSIS ,CANCER relapse - Abstract
Follicular lymphoma (FL) is characterized by an initial response to treatment with inevitable relapse. We evaluated chemoimmunotherapy resistance (CIR resistance) including transformation. We identified patients who received rituximab combination therapy for symptomatic FL. CIR resistance was defined as disease progression during rituximab-based chemoimmunotherapy, rituximab maintenance or within 6 months of treatment completion. Our primary outcome was time to early progression (CIR resistance). Between July 2006 and April 2010, 132 patients met the inclusion criteria and 22 (16.7%) demonstrated CIR resistance with a median follow-up of 33 months. High-risk Follicular Lymphoma International Prognostic Index (FLIPI) score was predictive of CIR resistance (hazard ratio [HR] 2.43; 95% confidence interval [CI], 1.4-4.1; p = 0.001). Overall, eight patients (36.3%) transformed (biopsy-proven), with no transformation in the chemoimmunotherapy responder group. Median overall survival in the CIR resistant group was 47 months. Patients with CIR resistance had high rates of histologic transformation and shorter survival with poor response to next therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
6. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant.
- Author
-
Villa, Diego, Gubbay, Jonathan, Sutherland, D. Robert, Laister, Robert, McGeer, Allison, Cooper, Curtis, Fortuno III, Edgardo S., Xu, Wei, Shi, Lily, Kukreti, Vishal, Crump, Michael, and Kuruvilla, John
- Subjects
H1N1 influenza ,STEM cell transplantation ,RITUXIMAB ,IMMUNOGENETICS ,VACCINE safety ,SYSTEMIC family therapy ,LYMPHOID tissue ,VACCINATION ,TUMORS - Abstract
This is a randomized trial evaluating the safety and immunogenicity of one or two doses of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies. Adults with a lymphoid malignancy receiving active systemic therapy, or within a year after autologous stem cell transplant, received one dose of AS03-adjuvanted A/California/7/2009 (H1N1) vaccine, and were randomized 21 days later to a second dose or no further vaccination. The primary outcomes were seroprotection and seroconversion rates by hemagglutination inhibition 21 and 42 days after initial vaccination. Twenty-two patients received one dose, and 20 patients received a second dose. Seroconversion rates at day 21 were 30% (one dose) and 5% (two doses), and subsequently 30% for both groups at day 42. Seroprotection rates at day 21 were 40% (one dose) and 15% (two doses), and subsequently 35% (one dose) and 40% (two doses) at day 42. Differences in serologic endpoints were not statistically significant between both study arms at day 42. Patients with low levels of B-cells (CD19-positive) had low seroconversion rates on days 21 (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.59-0.93, p = 0.043) and 42 (OR 0.12, 95% CI 0.01-1.07, p = 0.058). Only three of the 14 patients who received rituximab achieved seroprotective titers by day 42. Patients with lymphoid malignancies did not achieve rates of seroconversion or seroprotection seen in healthy subjects despite a second dose and the use of an adjuvant. Notwithstanding suboptimal immunogenicity, seasonal and pandemic influenza vaccination should continue to be recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
7. Rituximab-Induced Coronary Vasospasm.
- Author
-
Lee, Linda and Kukreti, Vishal
- Subjects
- *
RITUXIMAB , *B cell lymphoma , *HEMODYNAMICS , *ISCHEMIA , *CORONARY vasospasm - Abstract
Rituximab has improved the treatment of B-cell non-Hodgkin lymphomas. While it is generally well tolerated, serious adverse effects including infusion reactions with hemodynamic compromise and cardiac arrhythmias or ischemia are possible. We report a case of coronary vasospasm occurring during a rituximab infusion in a patient with minimal tumour burden and who had no cardiac risk factors. This case highlights that determination of the cause of ischemia is important and may identify some patients who can be successfully rechallenged. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.